A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects with Recalcitrant Discoid Lupus Erythematosus (DL
|Effective start/end date||3/1/12 → 2/28/14|
- Celgene Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.